P1003: RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY. - KIVIRID

P1003: RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY.

Authors: Ciro Rinaldi, Kristian Boasman, Matthew Simmonds

Published: 2023-08-08

DOI: 10.1097/01.hs9.0000970916.77031.e7

Source: Full article

Abstract

No abstract found.